Aude Le Roy
Research Subjects
Aude Le Roy has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Olive
Team Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille University UM105 and Paoli-Calmettes Institute, Marseille, France
70 shared publications - Laurent Gorvel
Immunity and Cancer Team, Cancer Research Center of Marseille, CRCM, INSERM U1068, CNRS UMR7258, Aix-Marseille University U105, Marseille, France
70 shared publications - Stéphane Fattori
Immunity and Cancer Team, Cancer Research Center of Marseille, CRCM, INSERM U1068, CNRS UMR7258, Aix-Marseille University U105, Marseille, France
70 shared publications - Nicolas Boucherit
Team Immunity and Cancer, Centre de Recherche en Cancerologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli–Calmettes, Aix–Marseille University, UM105, Marseille, France
69 shared publications - Amandine Anastasio
Centre de Recherche en Cancérologie de Marseille, INSERM U1068, CNRS UMR7258, Aix Marseille Université U105, Institut Paoli Calmettes, Marseille, France
38 shared publications - Anne-Charlotte Le Floch
Centre de Recherche en Cancérologie de Marseille, INSERM U1068, CNRS UMR7258, Aix Marseille Université U105, Institut Paoli Calmettes, Marseille, France
38 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Supplementary Figure S4. Anti-BTN2A1 107G3B5 mAb characterization.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Supplementary Figure S4. Anti-BTN2A1 107G3B5 mAb characterization.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Supplementary Figure S5. Cytotoxicity assays of 4 cancer cell lines (PC3, KARPAS, 697 and SUP-T1) and primary ALL blasts (n=4) using Annexin and 7-AAD labelling.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Supplementary Figure S5. Cytotoxicity assays of 4 cancer cell lines (PC3, KARPAS, 697 and SUP-T1) and primary ALL blasts (n=4) using Annexin and 7-AAD labelling.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Movie 1 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Visualization of Vγ9Vδ2 T cells (E) and SUP-T1 (T) coculture using a label-free method within 20 hours. Ratio T/E = 1/2. Cells treated with 10ug/ml of mIgG1 control antibody.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie 1 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Visualization of Vγ9Vδ2 T cells (E) and SUP-T1 (T) coculture using a label-free method within 20 hours. Ratio T/E = 1/2. Cells treated with 10ug/ml of mIgG1 control antibody.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Supplementary Figure S1. Gating strategy of ALL blasts and determination of the relative number of BTN2A and BTN3A molecules.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Supplementary Figure S1. Gating strategy of ALL blasts and determination of the relative number of BTN2A and BTN3A molecules.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Supplementary Figure S8. Segmentation of live cells using Refractive Index (RI).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Supplementary Figure S8. Segmentation of live cells using Refractive Index (RI).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Supplementary Figure 12. The caspase-3-specific inhibitor zDEVD-FMK inhibits the cleavage of GSDME.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Supplementary Figure 12. The caspase-3-specific inhibitor zDEVD-FMK inhibits the cleavage of GSDME.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Supplementary figure S11. Anti-BTN2A1 107G3B5 induces a colocalization of BTN3A1 and BTN2A1.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Supplementary figure S11. Anti-BTN2A1 107G3B5 induces a colocalization of BTN3A1 and BTN2A1.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Movie 3 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Visualization of Vγ9Vδ2 T cells (E) and Ishikawa (T) coculture using a label-free method within 20 hours. Ratio T/E = 1/2. Cells treated with 10ug/ml of mIgG1 control antibody.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie 3 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Visualization of Vγ9Vδ2 T cells (E) and Ishikawa (T) coculture using a label-free method within 20 hours. Ratio T/E = 1/2. Cells treated with 10ug/ml of mIgG1 control antibody.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Movie 2 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Visualization of Vγ9Vδ2 T cells (E) and SUP-T1 (T) coculture using a label-free method within 20 hours. Ratio T/E = 1/2. Cells treated with 107G3B5 antibody (10ug/ml).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie 2 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Visualization of Vγ9Vδ2 T cells (E) and SUP-T1 (T) coculture using a label-free method within 20 hours. Ratio T/E = 1/2. Cells treated with 107G3B5 antibody (10ug/ml).